Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.

Infliximab (IFX) and adalimumab (ADL) drug levels and anti-drug antibodies (ADA) are assessed using a variety of techniques, therefore, results cannot accurately be compared for clinical purposes. The aim of this study was to test two infliximab (IFX) and adalimumab (ADL) ELISA versions, for drug le...

Descripción completa

Detalles Bibliográficos
Autores: Valor L, Hernández-Flórez D, de la Torre I, Llinares F, Rosas J, Yagüe J, Garrido J, Naredo E
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p7021
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/7021
Access Level:acceso abierto
id ES_39d1e3bc73e9efd0175320dfc81afc4d
oai_identifier_str oai:fisabio.fundanetsuite.com:p7021
network_acronym_str ES
network_name_str España
repository_id_str
spelling Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.Valor LHernández-Flórez Dde la Torre ILlinares FRosas JYagüe JGarrido JNaredo EInfliximab (IFX) and adalimumab (ADL) drug levels and anti-drug antibodies (ADA) are assessed using a variety of techniques, therefore, results cannot accurately be compared for clinical purposes. The aim of this study was to test two infliximab (IFX) and adalimumab (ADL) ELISA versions, for drug levels and ADA, to see whether they yield similar results.CLINICAL & EXPER RHEUMATOLOGY2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/7021CLINICAL AND EXPERIMENTAL RHEUMATOLOGYISSN: 0392856XISSNe: 1593098Xreponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p70212026-06-11T12:45:17Z
dc.title.none.fl_str_mv Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
title Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
spellingShingle Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L
title_short Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
title_full Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
title_fullStr Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
title_full_unstemmed Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
title_sort Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
dc.creator.none.fl_str_mv Valor L
Hernández-Flórez D
de la Torre I
Llinares F
Rosas J
Yagüe J
Garrido J
Naredo E
author Valor L
author_facet Valor L
Hernández-Flórez D
de la Torre I
Llinares F
Rosas J
Yagüe J
Garrido J
Naredo E
author_role author
author2 Hernández-Flórez D
de la Torre I
Llinares F
Rosas J
Yagüe J
Garrido J
Naredo E
author2_role author
author
author
author
author
author
author
description Infliximab (IFX) and adalimumab (ADL) drug levels and anti-drug antibodies (ADA) are assessed using a variety of techniques, therefore, results cannot accurately be compared for clinical purposes. The aim of this study was to test two infliximab (IFX) and adalimumab (ADL) ELISA versions, for drug levels and ADA, to see whether they yield similar results.
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/7021
url https://fisabio.portalinvestigacion.com/publicaciones/7021
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv CLINICAL & EXPER RHEUMATOLOGY
publisher.none.fl_str_mv CLINICAL & EXPER RHEUMATOLOGY
dc.source.none.fl_str_mv CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
ISSN: 0392856X
ISSNe: 1593098X
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406194935791616
score 15.812429

Similares en LA Referencia